| Trial | Random sequence generation | Allocation concealment | Participant/personnel blinding | Blinding of outcome assessment | Incomplete outcome data, % loss to follow-up | Selective reporting | Other sources of bias | Overall risk |
| Abdalla, 2015 | Low risk | Unclear | Low risk | Unclear | Low risk, 0% | Unclear | Unclear | High | Aghdaii, 2015 | Low risk | Unclear | Unclear | Low risk | Unclear, N/R | Unclear | Unclear | High | Aydogan, 2014 | Low risk | Low risk | Low risk | Low risk | Low risk, 0% | Unclear | Low risk | Low | Baradari, 2017 | High risk | Low risk | Low risk | Low risk | Low risk, 3.5% | Low risk | Low risk | Low | Erdogan, 2013 | Low risk | Unclear | Low risk | Unclear | Low risk, 0% | Unclear | Unclear | High | Hosseinzadeh, 2013 | Low risk | Unclear | Low risk | Low risk | Unclear, N/R | Unclear | Low risk | Moderate | Iwata, 2009 | Low risk | Unclear | Unclear | Low risk | Unclear, N/R | Unclear | Unclear | High | Ozgul, 2013 | Low risk | Unclear | Low risk | Unclear | Unclear, N/R | Unclear | Unclear | High | Smischney, 2012 | Low risk | Low risk | Low risk | Low risk | Low risk, 0% | Unclear | Low risk | Low | Vora, 2005 | Unclear | Unclear | Low risk | Unclear | Unclear, N/R | High risk | Unclear | High |
|
|